Opko Health Inc

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    Analysts Drastically Reduced Target Price for Opko Health in March

    Wall Street analysts expect an upside potential of 107.39% for Opko Health (OPK) based on the company’s closing price on March 26.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Here Are Opko Health’s Major R&D Programs in 2018

    Opko Health (OPK) is focused on advancing multiple research and development (or R&D) programs including label expansion of Rayaldee and the development of novel therapies in 2018.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    A Look at Opko Health’s Expense Projections for 2018

    In its third-quarter earnings conference call, Opko Health (OPK) has forecasted its total costs and expenses for the fourth quarter to fall in the range of $280 million and $290 million.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Rayaldee Is a Key Revenue Driver for Opko Health

    In its third-quarter earnings conference call, Opko Health (OPK) forecasted its total product revenues to fall in the range of $28 million to $32 million in the fourth quarter.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Men’s Health Is a Key Focus Area for Opko Health

    Opko Health (OPK) is focused on advancing the penetration of its 4Kscore blood test.

    By Margaret Patrick
  • uploads///pills _
    Company & Industry Overviews

    What Analysts Recommend for Opko Health in November

    In the third quarter, Opko Health reported revenues of $249.81 million, which is a YoY rise of 1.53%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    OPKO Health Expects Its Loss per Share to Shrink This Year

    In the third quarter, OPKO Health (OPK) expects research and development expenses of $33 million–$38 million, and foresees its total operating expenses falling to $285 million–$305 million.

    By Margaret Patrick
  • uploads///medicine _
    Company & Industry Overviews

    OPKO Health’s Q3 2018 Revenue Expectations

    In the third quarter, OPKO Health (OPK) expects service revenue of $200 million–$220 million, assuming stable reimbursement rates and a small rise in volumes.

    By Margaret Patrick
  • uploads///Opko Health analysts
    Earnings Report

    Opko Health: Q2 Expenditures, Developments, Recommendations

    Opko Health’s (OPK) cost of revenues declined from $157.4 million in Q2 2017 to $150.1 million in Q2 2018.

    By Daniel Collins
  • uploads///Opko Health
    Earnings Report

    How Opko Health Fared in the Second Quarter of 2018

    Opko Health (OPK) generated net revenues of $263.7 million in the second quarter of 2018 compared to $292.6 million in Q2 of 2017.

    By Daniel Collins
  • uploads///medications __
    Company & Industry Overviews

    Why Citius Pharmaceuticals Stock Rose 31% in Week Ended July 13

    In the week ended July 13, Citius Pharmaceuticals (CTXR) stock rose 31% to $3.09, from $2.35 on July 6. Since July 10, it has grown consistently.

    By Daniel Collins
  • uploads///rayaldee
    Company & Industry Overviews

    Rayaldee Could Boost Opko Health’s Revenue in 2018 and Beyond

    Opko Health’s (OPK) Rayaldee generated revenues of $3.7 million in the first quarter. Rayaldee had a solid uptake that quarter.

    By Daniel Collins
  • uploads///molecule _
    Company & Industry Overviews

    Wall Street Analysts: Mostly Positive on Opko Health in July

    On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.

    By Daniel Collins
  • uploads///Nephrology
    Company & Industry Overviews

    How Amgen’s Nephrology Drugs Are Positioned after 2Q17?

    In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Why Quest Diagnostics’ Five Point Business Strategy Matters in 2016

    If Quest Diagnostics succeeds in implementing its five-point business strategy going forward, it should boost the company’s share price and USMV.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Quest Diagnostics’ Growth Restoration Strategy

    Quest Diagnostics has been focusing on developing sales and marketing expertise, increasing esoteric testing, and building relationships with hospitals.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Covance Drug Development Drives LabCorp’s 1Q16 Revenue Growth

    In 1Q16, LabCorp’s (LH) contract research organization business, Covance Drug Development, accounted for 30.7% of the company’s total revenues.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    LabCorp’s Growth Drivers in 1Q16: Organic Growth, Acquisitions

    In 1Q16, LabCorp’s (LH) national clinical laboratory business, LabCorp Diagnostics, accounted for 69.3% of the company’s total revenues.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Revenue Growth Initiatives Drove LabCorp’s Performance in 1Q16

    In 1Q16, LabCorp (LH) reported strong revenue and earnings growth due to the effective implementation of multiple strategic initiatives. LabCorp is the world’s leading healthcare diagnostics company.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Must-Read Notes on LabCorp’s 1Q16 Earnings and Conference Call

    Since the release of its 4Q15 earnings results, LabCorp has witnessed a solid 15.2% rise in its share price from $108.60 on February 18, 2016, to $125.10 on April 25, 2016, mainly due to strong business fundamentals.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI News as of March 16: Mid-Caps Under Pressure

    Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI on a Downward Slope, but How Steep?

    On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.

    By Peter Neil
  • uploads///Graph Part  OCt
    Company & Industry Overviews

    Analyzing Juno Therapeutics’ Performance until September 2015

    Juno Therapeutics (JUNO) is a mid-cap stock with a market cap of ~$4.75 billion. The stock rose by 8.6%. It outperformed all of the biotech stocks.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Seattle Genetics Leads XBI Mid-Cap Stocks

    Seattle Genetics (SGEN) rose 14.56% for the week ended September 11, 2015. The stock closed at $45.01 and moved back to 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    XBI Stocks: 33% Are Trading above the 20-Day Moving Averages

    XBI fell substantially in the moving averages. From August 10–17, 2015, only 32.63% of the stocks were trading above the 20-day moving averages.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB Outperforms XBI: Top 10 Mid-Cap Stocks

    The top ten mid-cap stocks from IBB outperformed the top ten mid-cap stocks from the SPDR S&P Biotechnology ETF (XBI) for the week ending August 7.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.